Good morning, everyone, and how are you today? 'Tis the middle of the week and here on the Pharmalot corporate campus this means scrambling to get the short people to their respective schoolhouses and updating our never-ending to-do list. We have a hunch that you can somehow relate. So feel free to join us as we brace ourselves for the day ahead with a cup or two of stimulation. Meanwhile, here are the tidbits. Hope that you survive and, if you do, stay in touch...
Doctor With Royalties Testifies J&J Implant Not Defective (Bloomberg News)
FDA Approves Sanofi And Isis Hyper-Cholesterol Drug (Bloomberg News)
FDA Panel Backs Boehringer COPD Drug (Pharma Times)
Judge Dismisses Whistleblower Suit Against AstraZeneca (Pennsylvania Record)
AstraZeneca Sues Reinsurers Over Seroquel Settlement (Royal Gazette)
Roche Forecasts A Rise In Profits And Sales (Bloomberg News)
Sanofi Expects FDA Decision On Lemtrada MS Drug Later In 2012 (Reuters)
Roche Signs $187M CNS Deal With Afraxis (Pharma Times)
Serbian Police Probe Drugmaker For Organized Crime Ties (B92)
EDITOR'S NOTE: Please check this post for additional items during the day
2 Comments
Is the Sanofi MS drug Lemtrade or Lemtrada? Inquiring minds....
Arlene
Lemtrada, of course. I must have been daydreaming about getting more coffee, which I obviously need quite desperately. Thanks for the close read.
ed